[1]
|
唐晓蕾, 李彩凤, 赵顺英. 儿童结缔组织病相关肺损害[J]. 中国循证儿科杂志, 2016, 11(2): 148-156.
|
[2]
|
徐雪峰, 蒋敏, 刘秀云, 等. 儿童免疫相关性疾病临床实用热点问题专家建议系列之二——中国儿童结缔组织疾病相关间质性肺病变诊治专家建议[J]. 中国实用儿科杂志, 2020, 35(3): 174-179.
https://doi.org/10.19538/j.ek2020030602
|
[3]
|
Shao, T., Shi, X., Yang, S., et al. (2021) Interstitial Lung Disease in Connective Tissue Disease: A Common Lesion with Heterogeneous Mechanisms and Treatment Considerations. Fron-tiers in Immunology, 12, Article ID: 684699.
https://doi.org/10.3389/fimmu.2021.684699
|
[4]
|
Lafyatis, R., O’Hara, C., Feghali-Bostwick, C.A., et al. (2007) B Cell Infiltration in Systemic Sclerosis-Associated Interstitial Lung Disease. Arthritis and Rheumatism, 56, 3167-3168. https://doi.org/10.1002/art.22847
|
[5]
|
Nakazawa, M., Suzuki, K., Takeshita, M., et al. (2021) Distinct Expression of Coinhibitory Molecules on Alveolar T Cells in Patients with Rheumatoid Arthritis-Associated and Idiopathic Inflam-matory Myopathy-Associated Interstitial Lung Disease. Arthritis & Rheumatology (Hoboken, NJ), 73, 576-586. https://doi.org/10.1002/art.41554
|
[6]
|
Karampitsakos, T., Woolard, T., Bouros, D., et al. (2017) Toll-Like Recep-tors in the Pathogenesis of Pulmonary Fibrosis. European Journal of Pharmacology, 808, 35-43. https://doi.org/10.1016/j.ejphar.2016.06.045
|
[7]
|
Bonella, F. and Costabel, U. (2014) Biomarkers in Connective Tissue Disease-Associated Interstitial Lung Disease. Seminars in Respiratory and Critical Care Medicine, 35, 181-200. https://doi.org/10.1055/s-0034-1371527
|
[8]
|
Newton, C.A., Batra, K., Torrealba, J., et al. (2016) Telo-mere-Related Lung Fibrosis Is Diagnostically Heterogeneous but Uniformly Progressive. The European Respiratory Journal, 48, 1710-1720.
https://doi.org/10.1183/13993003.00308-2016
|
[9]
|
Juge, P.A., Lee, J.S., Ebstein, E., et al. (2018) MUC5B Pro-moter Variant and Rheumatoid Arthritis with Interstitial Lung Disease. The New England Journal of Medicine, 379, 2209-2219. https://doi.org/10.1056/NEJMoa1801562
|
[10]
|
Lee, J.S. and Fischer, A. (2016) Current and Emerging Treatment Options for Interstitial Lung Disease in Patients with Rheumatic Disease. Expert Review of Clinical Immunol-ogy, 12, 509-520.
https://doi.org/10.1586/1744666X.2016.1139454
|
[11]
|
中国医师协会风湿免疫科医师分会风湿病相关肺血管/间质病学组, 国家风湿病数据中心. 2018中国结缔组织病相关间质性肺病诊断和治疗专家共识[J]. 中华内科杂志, 2018, 57(8): 558-565.
https://doi.org/10.3760/cma.j.issn.0578-1426.2018.08.005
|
[12]
|
Salles, G., Barrett, M., Foà, R., et al. (2017) Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. Advances in Therapy, 34, 2232-2273. https://doi.org/10.1007/s12325-017-0612-x
|
[13]
|
Vacchi, C., Manfredi, A., Cassone, G., et al. (2021) Efficacy and Safety of Rituximab in the Treatment of Connective Tissue Disease-Related Interstitial Lung Disease. Drugs in Context, 10. https://doi.org/10.7573/dic.2020-8-7
|
[14]
|
François, A., Chatelus, E., Wachsmann, D., et al. (2013) B Lymphocytes and B-Cell Activating Factor Promote Collagen and Profibrotic Markers Expression by Dermal Fibro-blasts in Systemic Sclerosis. Arthritis Research & Therapy, 15, R168. https://doi.org/10.1186/ar4352
|
[15]
|
Duarte, A.C., Cordeiro, A., Fernandes, B.M., et al. (2019) Rituximab in Connective Tissue Disease-Associated Interstitial Lung Disease. Clinical Rheumatology, 38, 2001-2009. https://doi.org/10.1007/s10067-019-04557-7
|
[16]
|
Fui, A., Ber-gantini, L., Selvi, E., et al. (2020) Rituximab Therapy in Interstitial Lung Disease Associated with Rheumatoid Arthritis. Internal Medicine Journal, 50, 330-336. https://doi.org/10.1111/imj.14306
|
[17]
|
Sircar, G., Goswami, R.P., Sircar, D., et al. (2018) Intravenous Cyclophosphamide vs Rituximab for the Treatment of Early Diffuse Scleroderma Lung Disease: Open Label, Randomized, Controlled Trial. Rheumatology (Oxford, England), 57, 2106-2113. https://doi.org/10.1093/rheumatology/key213
|
[18]
|
Kearsley-Fleet, L., Sampath, S., McCann, L.J., et al. (2019) Use and Effectiveness of Rituximab in Children and Young People with Juvenile Idiopathic Arthritis in a Cohort Study in the United Kingdom. Rheumatology (Oxford, England), 58, 331-335. https://doi.org/10.1093/rheumatology/key306
|
[19]
|
Oddis, C.V., Reed, A.M., Aggarwal, R., et al. (2013) Rituximab in the Treatment of Refractory Adult and Juvenile Dermatomyositis and Adult Polymyositis: A Randomized, Place-bo-Phase Trial. Arthritis and Rheumatism, 65, 314-324.
https://doi.org/10.1002/art.37754
|
[20]
|
Spencer, C.H., Rouster-Stevens, K., Gewanter, H., et al. (2017) Biologic Therapies for Refractory Juvenile Dermatomyositis: Five Years of Experience of the Childhood Arthritis and Rheuma-tology Research Alliance in North America. Pediatric Rheumatology Online Journal, 15, 50. https://doi.org/10.1186/s12969-017-0174-0
|
[21]
|
Nishi, K., Ogura, M., Tamai, N., et al. (2022) Successful Rituxi-mab Treatment for Severe Rapidly Progressive Interstitial Lung Disease with Anti-MDA5 Antibody-Positive Juvenile Dermatomyositis: A Case Report and Literature Review. Pediatric Rheumatology Online Journal, 20, 60. https://doi.org/10.1186/s12969-022-00723-5
|
[22]
|
Mahmoud, I., Jellouli, M., Boukhris, I., et al. (2017) Efficacy and Safety of Rituximab in the Management of Pediatric Systemic Lupus Erythematosus: A Systematic Review. The Journal of Pediatrics, 187, 213-219.e2.
https://doi.org/10.1016/j.jpeds.2017.05.002
|
[23]
|
McAtee, C.L., Lubega, J., Underbrink, K., et al. (2021) Associa-tion of Rituximab Use with Adverse Events in Children, Adolescents, and Young Adults. JAMA Network Open, 4, e2036321.
https://doi.org/10.1001/jamanetworkopen.2020.36321
|
[24]
|
De Benedetti, F., Brunner, H.I., Ruperto, N., et al. (2012) Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis. The New England Journal of Medicine, 367, 2385-2395. https://doi.org/10.1056/NEJMoa1112802
|
[25]
|
Yokota, S., Itoh, Y., Morio, T., et al. (2016) To-cilizumab in Systemic Juvenile Idiopathic Arthritis in a Real-World Clinical Setting: Results from 1 Year of Postmarket-ing Surveillance Follow-Up of 417 Patients in Japan. Annals of the Rheumatic Diseases, 75, 1654-1660. https://doi.org/10.1136/annrheumdis-2015-207818
|
[26]
|
Mallalieu, N.L., Wimalasundera, S., Hsu, J.C., et al. (2019) Intravenous Dosing of Tocilizumab in Patients Younger than Two Years of Age with Systemic Juvenile Idiopathic Ar-thritis: Results from an Open-Label Phase 1 Clinical Trial. Pediatric Rheumatology Online Journal, 17, 57. https://doi.org/10.1186/s12969-019-0364-z
|
[27]
|
Malattia, C., Ruperto, N., Pederzoli, S., et al. (2020) Tocilizumab May Slow Radiographic Progression in Patients with Systemic or Polyarticular-Course Juvenile Idiopathic Arthritis: Post Hoc Radiographic Analysis from Two Randomized Controlled Trials. Arthritis Research & Therapy, 22, 211. https://doi.org/10.1186/s13075-020-02303-y
|
[28]
|
Cabrera, N., Duquesne, A., Desjonquères, M., et al. (2016) To-cilizumab in the Treatment of Mixed Connective Tissue Disease and Overlap Syndrome in Children. RMD Open, 2, e000271. https://doi.org/10.1136/rmdopen-2016-000271
|
[29]
|
Sukharomana, M., Udomittipong, K., Ru-angchira-Urai, R., et al. (2022) Nonspecific Interstitial Pneumonia in Refractory Systemic Juvenile Idiopathic Arthritis Responded to Tocilizumab Treatment. Asian Pacific Journal of Allergy and Immunology, 40, 172-176.
|
[30]
|
Maruyama, Y., Shigemura, T., Kobayashi, N., et al. (2022) Efficacy of Tocilizumab for Interstitial Lung Disease Associated with Polyarticular Juvenile Idiopathic Arthritis. Pediatrics International: Official Journal of the Japan Pediatric Society, 64, e14737. https://doi.org/10.1111/ped.14737
|
[31]
|
Maniscalco, V., Marrani, E., Rossi, E., et al. (2021) Too Young to Fail: A Case Report on the Effectiveness of Tocilizumab for Paediatric Systemic Sclerosis-Associated Interstitial Lung Disease. Scandinavian Journal of Rheumatology, 50, 491-492. https://doi.org/10.1080/03009742.2021.1881154
|
[32]
|
张洲, 王秀丽, 赵成广, 等. 阿达木单抗治疗幼年特发性关节炎的疗效分析[J]. 中国医科大学学报, 2022, 51(8): 756-759.
|
[33]
|
Brunner, H.I., Nanda, K., Toth, M., et al. (2020) Safety and Effectiveness of Adalimumab in Patients with Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven-Year Interim Results. Arthritis Care & Research, 72, 1420-1430. https://doi.org/10.1002/acr.24044
|
[34]
|
Park, J.K., Yoo, H.G., Ahn, D.S., et al. (2012) Successful Treatment for Conventional Treatment-Resistant Dermatomyositis-Associated Interstitial Lung Disease with Adalimumab. Rheumatology International, 32, 3587-3590.
https://doi.org/10.1007/s00296-011-2220-4
|
[35]
|
Wang, C.R. (2017) Successful Treatment of Refractory Juvenile Dermatomyositis with Adalimumab. Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskel-etal Diseases, 23, 174-175.
https://doi.org/10.1097/RHU.0000000000000514
|
[36]
|
Jin, J. and Yu, H. (2022) Use of Adalimumab in a Child with Juvenile Dermatomyositis and Calcinosis. Indian Journal of Pediatrics, 89, 1270. https://doi.org/10.1007/s12098-022-04332-8
|
[37]
|
Schiffenbauer, A., Garg, M., Castro, C., et al. (2018) A Ran-domized, Double-Blind, Placebo-Controlled Trial of Infliximab in Refractory Polymyositis and Dermatomyositis. Semi-nars in Arthritis and Rheumatism, 47, 858-864.
https://doi.org/10.1016/j.semarthrit.2017.10.010
|
[38]
|
Campanilho-Marques, R., Deakin, C.T., Simou, S., et al. (2020) Retrospective Analysis of Infliximab and Adalimumab Treatment in a Large Cohort of Juvenile Dermatomyositis Patients. Arthritis Research & Therapy, 22, 79.
https://doi.org/10.1186/s13075-020-02164-5
|
[39]
|
Liu, D.W., Chen, J.J., Tang, X.M., et al. (2020) Infliximab Therapy and Outcomes in Patients with Polyarticular Juvenile Idiopathic Arthritis: A Single-Center Study in China. World Journal of Pediatrics: WJP, 16, 68-73.
https://doi.org/10.1007/s12519-019-00316-5
|
[40]
|
Chen, D., Wang, X.B., Zhou, Y., et al. (2013) Efficacy of In-fliximab in the Treatment for Dermatomyositis with Acute Interstitial Pneumonia: A Study of Fourteen Cases and Litera-ture Review. Rheumatology International, 33, 2455-2458.
https://doi.org/10.1007/s00296-012-2653-4
|
[41]
|
Huang, Y., Lin, W., Chen, Z., et al. (2019) Effect of Tumor Ne-crosis Factor Inhibitors on Interstitial Lung Disease in Rheumatoid Arthritis: Angel or Demon? Drug Design, Develop-ment and Therapy, 13, 2111-2125.
https://doi.org/10.2147/DDDT.S204730
|
[42]
|
Brunner, H.I., Abud-Mendoza, C., Viola, D.O., et al. (2020) Safety and Efficacy of Intravenous Belimumab in Children with Systemic Lupus Erythematosus: Results from a Randomised, Placebo-Controlled Trial. Annals of the Rheumatic Diseases, 79, 1340-1348. https://doi.org/10.1136/annrheumdis-2020-217101
|
[43]
|
Guzman, M. and Hui-Yuen, J.S. (2020) Management of Pediatric Systemic Lupus Erythematosus: Focus on Belimumab. Drug Design, Development and Therapy, 14, 2503-2513. https://doi.org/10.2147/DDDT.S216193
|
[44]
|
曾萍, 曾华松, 唐雪梅, 等. 贝利尤单抗治疗中国儿童系统性红斑狼疮28周有效性和安全性分析: 一项回顾性多中心真实世界的初步研究[J]. 中国实用儿科杂志, 2021, 36(11): 858-868.
https://doi.org/10.19538/j.ek2021110612
|
[45]
|
Mwangi, J., Litteken, C., Gorthi, R., et al. (2021) Belimumab in the Treatment of Connective Tissue Disease-Associated Interstitial Lung Disease: Case Report and Literature Review. Cure-us, 13, e19218.
https://doi.org/10.7759/cureus.19218
|
[46]
|
Brunner, H.I., Wong, R., Nys, M., et al. (2020) Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic Arthritis. Paediatric Drugs, 22, 653-672. https://doi.org/10.1007/s40272-020-00422-2
|
[47]
|
Vicente-Rabaneda, E.F., Atienza-Mateo, B., Blanco, R., et al. (2021) Efficacy and Safety of Abatacept in Interstitial Lung Disease of Rheumatoid Arthritis: A Systematic Literature Re-view. Autoimmunity Reviews, 20, Article ID: 102830.
https://doi.org/10.1016/j.autrev.2021.102830
|
[48]
|
Ruperto, N., Brunner, H.I., Synoverska, O., et al. (2021) Tofa-citinib in Juvenile Idiopathic Arthritis: A Double-Blind, Placebo-Controlled, Withdrawal Phase 3 Randomised Trial. The Lancet (London, England), 398, 1984-1996.
https://doi.org/10.1016/S0140-6736(21)01255-1
|
[49]
|
Yu, Z., Wang, L., Quan, M., et al. (2021) Successful Man-agement with Janus Kinase Inhibitor Tofacitinib in Refractory Juvenile Dermatomyositis: A Pilot Study and Literature Review. Rheumatology (Oxford, England), 60, 1700-1707.
https://doi.org/10.1093/rheumatology/keaa558
|
[50]
|
Chen, Z., Wang, X. and Ye, S. (2019) Tofacitinib in Amyopa-thic Dermatomyositis-Associated Interstitial Lung Disease. The New England Journal of Medicine, 381, 291-293. https://doi.org/10.1056/NEJMc1900045
|
[51]
|
Vacchi, C., Manfredi, A., Cassone, G., et al. (2021) Tofacitinib for the Treatment of Severe Interstitial Lung Disease Related to Rheumatoid Arthritis. Case Reports in Medicine, 2021, Arti-cle ID: 6652845.
https://doi.org/10.1155/2021/6652845
|